1. Subbarao K, Mahanty S. Respiratory Virus Infections: Understanding COVID-19. Immunity. 2020;52(6):905-9. [
DOI:10.1016/j.immuni.2020.05.004] [
PMID] [
PMCID]
2. Lal SK. Molecular biology of the SARS-coronavirus: Springer; 2010. [
DOI:10.1007/978-3-642-03683-5]
3. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J. 2015;12(1):1-21. [
DOI:10.1186/s12985-015-0439-5] [
PMID] [
PMCID]
4. Mohanty SK, Satapathy A, Naidu MM, Mukhopadhyay S, Sharma S, Barton LM, et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) - anatomic pathology perspective on current knowledge. Diagn Pathol. 2020;15:1-17. [
DOI:10.1186/s13000-020-01017-8] [
PMID] [
PMCID]
5. Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87(23):12552-61. [
DOI:10.1128/JVI.01890-13] [
PMID] [
PMCID]
6. Sallenave J-M, Guillot L. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets? Front Immunol. 2020;11:1229. [
DOI:10.3389/fimmu.2020.01229] [
PMID] [
PMCID]
7. Karimian M, Jamshidbeigi A, Badfar G, Azami M. Laboratory findings in coronavirus disease 2019 (COVID-19) patients: a comprehensive systematic review and meta-analysis. medRxiv. 2020:2020-06. [
DOI:10.1101/2020.06.07.20124602]
8. Samprathi M, Jayashree M. Biomarkers in COVID-19: An Up-To-Date Review. Front Pediatr. 2021;8:607647. [
DOI:10.3389/fped.2020.607647] [
PMID] [
PMCID]
9. Hong L-Z, Shou Z-X, Zheng D-M, Jin X. The most important biomarker associated with coagulation and inflammation among COVID-19 patients. Mol Cell Biochem. 2021;476(7):2877-85. [
DOI:10.1007/s11010-021-04122-4] [
PMID] [
PMCID]
10. Eljilany I, Elzouki A-N. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. Vasc Health Risk Manag. 2020(16):455-62. [
DOI:10.2147/VHRM.S280962] [
PMID] [
PMCID]
11. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021;26(3):107-8. [
DOI:10.1136/bmjebm-2020-111536] [
PMID] [
PMCID]
12. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4-5):490-5. [
DOI:10.1016/j.autrev.2014.01.008] [
PMID]
13. Traub M, Marshall K. Psoriasis--pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev. 2007;12(4):319-30.
14. Liu Y, Yang G, Zhang J, Xing K, Dai L, Cheng L, et al. Anti-TNF-α monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis. Int Immunopharmacol. 2015;28(1):731-43. [
DOI:10.1016/j.intimp.2015.07.036] [
PMID]
15. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-15. [
DOI:10.1016/j.jaad.2007.09.010] [
PMID]
16. Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021;147(1):60-71. [
DOI:10.1016/j.jaci.2020.10.007] [
PMID] [
PMCID]
17. Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, et al. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. J Am Acad Dermatol. 2021;84(2):513-7. [
DOI:10.1016/j.jaad.2020.10.046] [
PMID] [
PMCID]
18. Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. J Dermatolog Treat. 2022;33(2):699-703. [
DOI:10.1080/09546634.2020.1789051] [
PMID]
19. Piaserico S, Gisondi P, Cazzaniga S, Naldi L. Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. Am J Clin Dermatol. 2020;21(5):749-51. [
DOI:10.1007/s40257-020-00552-w] [
PMID] [
PMCID]
20. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(suppl 2):ii65-ii8. [
DOI:10.1136/ard.2004.031237] [
PMID] [
PMCID]
21. Yokota S, Miyamae T, Kuroiwa Y, Nishioka K. Novel Coronavirus Disease 2019 (COVID-19) and Cytokine Storms for More Effective Treatments from an Inflammatory Pathophysiology. J Clin Med. 2021;10(4):801. [
DOI:10.3390/jcm10040801] [
PMID] [
PMCID]
22. Que Y, Hu C, Wan K, Hu P, Wang R, Luo J, et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol. 2022;41(2):217-30. [
DOI:10.1080/08830185.2021.1884248] [
PMID] [
PMCID]
23. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382-5. [
DOI:10.1080/22221751.2020.1729069] [
PMID] [
PMCID]
24. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, et al. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nat Commun. 2020;11(1):2251. [
DOI:10.1038/s41467-020-16256-y] [
PMID] [
PMCID]
25. Atzeni F, Masala IF, Rodríguez-Carrio J, Ríos-Garcés R, Gerratana E, La Corte L, et al. The Rheumatology Drugs for COVID-19 Management: Which and When? J Clin Med. 2021;10(4):783. [
DOI:10.3390/jcm10040783] [
PMID] [
PMCID]
26. Bonek K, Roszkowski L, Massalska M, Maslinski W, Ciechomska M. Biologic drugs for rheumatoid arthritis in the context of biosimilars, genetics, epigenetics and COVID-19 treatment. Cells. 2021;10(2):323. [
DOI:10.3390/cells10020323] [
PMID] [
PMCID]
27. Tursi A, Angarano G, Monno L, Saracino A, Signorile F, Ricciardi A, et al. COVID-19 infection in Crohn's disease under treatment with adalimumab. Gut. 2020;69(7):1364-5. [
DOI:10.1136/gutjnl-2020-321240] [
PMID]
28. Kara Polat A, Oguz Topal I, Karadag AS, Aksoy H, Koku Aksu AE, Ozkur E, et al. The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. Dermatol Ther. 2021;34(1):e14691. [
DOI:10.1111/dth.14691] [
PMCID]
29. Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G. The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. Vaccines. 2020;8(4):728. [
DOI:10.3390/vaccines8040728] [
PMID] [
PMCID]